MUC1 and cancer: In addition, an antibody generated against the MUC1-C extracellular domain has been advanced for clinical evaluation as CAR-T cells (Poseida Pharmaceuticals) and is being developed as an antibody–drug conjugate by the NCI NExT Program for MUC1-C-expressing cancers [55].